1,004 research outputs found
Migration and Land Use Change in Europe: A Review
No full textMigration and Land Use Change in Europe: A ReviewBell, S., Alves, S., Silverinha de Oliveira, E and Zuin, A.2010PRJLiving Reviews of Landscape Research 4(2010)2http://www.livingreviews.org/lrlr-2010-
Saggio Introduttivo. Quindici anni di ‘Valori identitari e imprenditorialità’. Un percorso formativo e scientifico
No full textGli ‘universali’ del language maintenance e shift: un confronto tra gli oriundi veneti e friulani in Sudamerica
No full textThe Role of Surgery in Pleural Mesothelioma: A Journey through the Evidence, MARS 2 and Beyond
No full textPleural mesothelioma (PM) is a rare incurable disease, predominantly linked to asbestos exposure. Not only is diagnosis difficult, but treatment choices are often limited to systemic anti-cancer treatment with chemotherapy or immunotherapy. Surgery has been employed for decades, but its application has been fiercely debated despite some randomized controlled trials such as the recent Mesothelioma and Radical Surgery 2 (MARS 2) study. We provide a commentary on this controversial topic. © The Author(s) 2025
Relatório de revisão por pares para: Diálogos entre educação, cidade e patrimônio: investigando produções científicas brasileiras
No full textRevisão por pares do artigo:
SOUZA, R. S. R. e; DINIZ, M. Diálogos entre educação, cidade e patrimônio: investigando produções científicas brasileiras. Educ. Form., Fortaleza, v. 7, p. e6779, 2022. DOI: 10.25053/redufor.v7i1.6779. Disponível em: https://revistas.uece.br/index.php/redufor/article/view/6779.
Como citar este relatório:
ZUIN, A. L. A.; GRACIOLI, F. R. Relatório de revisão por pares para: diálogos entre educação, cidade e patrimônio: investigando produções científicas brasileiras. Educ. Form., 2022, Zenodo. Disponível em: https://doi.org/10.5281/zenodo.6817649.
Revisado por:
Aparecida Luzia Alzira Zuin (Universidade Federal de Rondônia, Porto Velho, Rondônia, RR, Brasil)
Filipe Rafael Gracioli (Instituto do Patrimônio Histórico e Artístico Nacional, Rio de Janeiro, Rio de Janeiro, RJ, Brasil
Migration and Land Use Change in Europe: A Review
No full textMigration and Land Use Change in Europe: A ReviewBell, S., Alves, S., Silverinha de Oliveira, E and Zuin, A.2010PRJLiving Reviews of Landscape Research 4(2010)2http://www.livingreviews.org/lrlr-2010-
Seed longevity and dormancy of four summer annual grass weeds in turf
No full textDigitaria sanguinalis, Eleusine indica, Setaria glauca and S. viridis are troublesome summer annual weeds in turf. For taking rational decisions on the necessity for the level and type of weed management, it is important to know when weeds are ready to emerge (dormancy status) and also how long weed seeds can survive in the soil. Seeds of these four species were buried 4.0–4.5 cm deep in steel mesh net bags placed under permanent turf and periodically exhumed for 3 years to evaluate viability and determine the dormancy/non-dormancy cycle.
D. sanguinalis, S. glauca and S. viridis showed the typical dormancy cycle of summer annual species, and their seed viability declined completely after 3 years of burial. In contrast, E. indica demonstrated unusual behaviour, with long persistence and no dormancy
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
No full textPatrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florence, Italy; 5Pediatric Department, Federico II University of Naples, Naples, Italy; 6Pediatric Gastroenterology, University of Messina, Messina, Italy; 7Gastroenterology and GI Endoscopy Unit, University Department of Pediatrics, Children’s Hospital, Brescia, Italy; 8Hepatology and Gastroenterology Unit, Bambino Gesù Hospital, Rome, Italy; 9Department of Pediatrics, Institute of Child Health, IRCSS Burlo Garofolo, Trieste, Italy; 10University of Padua, Padua, Italy; 11Pediatric Department, University of Palermo, G di Cristina Children’s Hospital, Palermo, Italy; 12Pediatric Unit, Buzzi Hospital, Milan, Italy; 13Pediatric Unit, Niguarda Hospital, Milan, Italy; 14Morgagni Hospital, Forlì, Italy; 15Emergency Pediatric Department, S Orsola Hospital, Bologna, Italy Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.Objectives: We investigated Ada efficacy in a retrospective, pediatric CD cohort who had failed previous infliximab treatment, with a minimum follow-up of 6 months.Methods: In this multicenter study, data on demographics, clinical activity, growth, laboratory values (CRP) and adverse events were collected from CD patients during follow-up. Clinical remission (CR) and response were defined with Pediatric CD Activity Index (PCDAI) score ≤10 and a decrease in PCDAI score of ≥12.5 from baseline, respectively.Results: A total of 44 patients were consecutively recruited (mean age 14.8 years): 34 of 44 (77%) had active disease (mean PCDAI score 24.5) at the time of Ada administration, with a mean disease duration of 3.4 (range 0.3–11.2) years. At 6, 12, and 18 months, out of the total of the enrolled population, CR rates were 55%, 78%, and 52%, respectively, with a significant decrease in PCDAI scores (P<0.01) and mean CRP values (mean CRP 5.7 and 2.4 mL/dL, respectively; P<0.01) at the end of follow-up. Steroid-free remission rates, considered as the total number of patients in CR who were not using steroids at the end of this study, were 93%, 95%, and 96% in 44 patients at 6, 12, and 18 months, respectively. No significant differences in growth parameters were detected. In univariate analysis of variables related to Ada efficacy, we found that only a disease duration >2 years was negatively correlated with final PCDAI score (P<0.01). Two serious adverse events were recorded: 1 meningitis and 1 medulloblastoma.Conclusion: Our data confirm Ada efficacy in pediatric patients as second-line biological therapy after infliximab failure. Longer-term prospective data are warranted to define general effectiveness and safety in pediatric CD patients. Keywords: pediatric Crohn’s disease, infliximab failure, adalimumab efficacy, adalimumab safet
- …
